• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Other Toxic Disorders - Pipeline Review, H2 2012 Product Image

Other Toxic Disorders - Pipeline Review, H2 2012

  • ID: 2233807
  • August 2012
  • 39 pages
  • Global Markets Direct

Other Toxic Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Other Toxic Disorders - Pipeline Review, H2 2012', provides an overview of the Other Toxic Disorders therapeutic pipeline. This report provides information on the therapeutic development for Other Toxic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Toxic Disorders. 'Other Toxic Disorders - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Toxic Disorders.
- A review of the Other Toxic Disorders products under development by companies READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Other Toxic Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Other Toxic Disorders 7
Other Toxic Disorders Therapeutics under Development by Companies 9
Other Toxic Disorders Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Other Toxic Disorders Therapeutics – Products under Development by Companies 15
Other Toxic Disorders Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Other Toxic Disorders Therapeutics Development 17
Syntrix Biosystems, Inc. 17
Other Toxic Disorders – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
Bungarus multicinctus-candidus antivenom - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Amifostine Trihydrate + Cisplatin + Gemcitabine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
bevacizumab - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RiVax + Alum - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NMDA Inhibitors - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
N-Acetylcysteine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Other Toxic Disorders Therapeutics - Dormant Products 31
Other Toxic Disorders – Product Development Milestones 32
Featured News & Press Releases 32
Jun 30, 2010: Aeolus’ AEOL 10150 Protects Lungs Against Mustard Gas Exposure In Animal Studies 32
Jun 29, 2010: Aeolus’ AEOL 10150 Provides Significant Protection Of Skin In Pre-Clinical Studies Of Mustard Gas Exposure 32
Jun 01, 2010: Baxter recalls Hylenex due to particulate matter 33
May 16, 2010: Halozyme Delivers Notice of Breach to Baxter Healthcare Due to HYLENEX Manufacturing Failures 33
Oct 05, 2009: Baxter Announces the Commercial Launch of HYLENEX at ACEP for Use in Pediatric Rehydration 34
Jan 22, 2008: Meritage Pharma Initiates Phase IIb Clinical Trial Of Oral Viscous Budesonide For Pediatric Patients With Eosinophilic Esophagitis 34
Jan 08, 2008: Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 35
Jun 01, 2007: Baxter Unveils Hylenex For Ophthalmic Surgery 36
Feb 14, 2007: Halozyme and Baxter Expand Global HYLENEX Collaboration 36
Feb 14, 2007: Halozyme Therapeutics and Baxter Present Promising Results for the Use of HYLENEX From the Infuse-Morphine Study 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Number of Products Under Development for Other Toxic Disorders, H2 2012 7
Products under Development for Other Toxic Disorders – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Syntrix Biosystems, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Other Toxic Disorders Therapeutics – Dormant Products 31

List of Figures
Number of Products under Development for Other Toxic Disorders, H2 2012 7
Products under Development for Other Toxic Disorders – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos